Implant-related infections represent a significant complication in various surgical fields, notably in dentistry, orthopedics, and cardiology. These infections not only compromise the success of the implant but can also lead to systemic complications and implant failure. This study aims to evaluate the prevalence, causative microorganisms, risk factors, and clinical outcomes of implant-related infections. Through a cross-sectional clinical analysis and laboratory culture identification, we assessed 120 patients with different types of medical implants over a 24-month period. Our findings show that Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa were the most commonly isolated pathogens. The study highlights the importance of early detection, surgical asepsis, and targeted antibiotic therapy in reducing the burden of implant-associated infections.

Implant-related infections (IRIs) have emerged as a critical concern in modern medicine, especially with the growing demand for prosthetic devices and surgical implants. These infections can affect dental implants, orthopedic prostheses, cardiovascular stents, and other medical devices. Despite advancements in aseptic techniques and implant materials, infection rates remain at 1–4% in orthopedic implants and even higher in certain high-risk populations.

The pathogenesis of IRIs is typically associated with the formation of bacterial biofilms on implant surfaces, which protect microorganisms from host immune responses and antimicrobial therapy. Biofilm-associated bacteria are highly resistant to antibiotics, making treatment difficult and often necessitating implant removal.

The present study investigates the epidemiology and microbiological profiles of IRIs, identifies potential predisposing factors, and discusses current management strategies, with an emphasis on preventive approaches.

Study Design and Population

This was a prospective observational study conducted between January 2023 and December 2024 in three tertiary care hospitals specializing in dental, orthopedic, and general surgical implants. A total of 120 patients (aged 18–75 years) with clinically suspected implant-related infections were included.

Inclusion Criteria

• Patients with clinical signs of infection (pain, swelling, purulence) around the implant site
• Positive culture from implant site or surrounding tissue
• Implants placed within the previous 12 months

Exclusion Criteria

• Patients with systemic infections not related to the implant
• Immunocompromised patients undergoing chemotherapy

Sample Collection

Swabs and tissue samples were collected from the implant site under sterile conditions. Explanted prostheses were subjected to sonication to dislodge biofilms.

Microbiological Analysis

All samples were cultured on blood agar, MacConkey agar, and Sabouraud dextrose agar (for fungal identification). Gram staining, catalase and coagulase tests, and antibiotic susceptibility testing were performed according to CLSI guidelines.

Data Collection

Demographic data, type of implant, time to infection, comorbidities (e.g., diabetes), surgical factors (duration, sterilization), and treatment outcomes were recorded.

Among the 120 patients evaluated, 42.5% were male and 57.5

The high prevalence of Staphylococcus species aligns with global findings, emphasizing the role of skin flora in perioperative contamination. Biofilm-associated resistance challenges the effectiveness of standard antibiotic protocols and highlights the need for combination therapies and new antimicrobial agents.

Notably, Pseudomonas aeruginosa was prevalent in orthopedic and cardiovascular implants, suggesting the need for broader-spectrum prophylactic strategies in such cases.

Preventive measures—including preoperative screening, optimized surgical techniques, and post-operative hygiene education—remain cornerstones of infection control. Emerging technologies, such as antimicrobial coatings and bacteriophage therapies, offer promising avenues for future intervention.

Our findings also support the growing importance of personalized risk assessment before implant surgery, especially in diabetic or immunocompromised patients.

Implant-related infections are a persistent and complex challenge in modern medicine. Early diagnosis, multidisciplinary management, and evidence-based prevention strategies are crucial to minimize complications. Ongoing research into biofilm disruption and novel antimicrobials is vital to improve clinical outcomes. Our study underscores the need for tailored clinical protocols based on implant type, patient risk profile, and microbial trends.